Searching for disease-modifying drugs in AD: Can we combine neuropsychological tools with biological markers?

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 1, 2014, Pages 173-186

  Caraci, Filippo ^a,b   Castellano, Sabrina ^a   Salomone, Salvatore ^a   Drago, Filippo ^a   Bosco, Paolo ^b   Di Nuovo, Santo ^a,b  

^a UNIVERSITY OF CATANIA   (Italy)

^b OASI RESEARCH INSTITUTE IRCCS   (Italy)

Author keywords

Alzheimer's disease; Biological markers; Disease modifying drugs; Mild cognitive impairment; Neuropsychological tests; Risk factors

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE;

ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG DESIGN; EVIDENCE BASED PRACTICE; FUNCTIONAL NEUROIMAGING; HUMAN; MENTAL DISEASE; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NEUROPROTECTION; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; PATHOGENESIS; RISK FACTOR;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; COGNITION DISORDERS; DRUG DISCOVERY; HUMANS; NEUROPSYCHOLOGICAL TESTS; OUTCOME ASSESSMENT (HEALTH CARE); PEPTIDE FRAGMENTS;

EID: 84896712004     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113129990103     Document Type: Article

References (140)

1. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol 2011; 7(3): 137-152.
2. Jellinger KA. Alzheimer 100--highlights in the history of Alzheimer research. J Neural Transm 2006; 113(11): 1603-1623.
3. Ballard C, Day S, Sharp S, Wing G, Sorensen S. Neuropsychiatric symptoms in dementia: importance and treatment considerations. Int Rev Psychiatry 2008; 20(4): 396-404.
4. Hardy J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 2009; 110(4): 1129-1134.
5. Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron 2010; 68(2): 270-281.
6. Lambert JC, Amouyel P. Genetics of Alzheimer's disease: new evidences for an old hypothesis? Curr Opin Genet Dev 2011; 21(3): 295-301.
7. Genin E, Hannequin D, Wallon D, et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry 2011; 16(9): 903-907.
8. Goate A, Hardy J. Twenty years of Alzheimer's disease-causing mutations. J Neurochem 2012; 120(Suppl 1): 3-8.
9. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010; 362(4): 329-344.
10. Walsh DM, Selkoe DJ. A beta oligomers - a decade of discovery. J Neurochem 2007; 101(5): 1172-1184.
11. Ittner LM, Gotz J. Amyloid-beta and tau--a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 2011; 12(2): 65-72.
12. Spires-Jones TL, Stoothoff WH, de Calignon A, Jones PB, Hyman BT. Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci 2009; 32(3): 150-159.
13. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer's disease: clinical trials and drug development. Lancet Neurol 2010; 9(7): 702-716.
14. Klafki HW, Staufenbiel M, Kornhuber J, Wiltfang J. Therapeutic approaches to Alzheimer's disease. Brain 2006; 129(Pt 11): 2840-2855.
15. Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br J Clin Pharmacol 2012; 73(4): 504-517.
16. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7(3): 270-279.
17. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7(3): 280-292.
18. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7(3): 263-269.
19. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256(3): 183-194.
20. Petersen RC. Early diagnosis of Alzheimer's disease: is MCI too late? Curr Alzheimer Res 2009; 6(4): 324-330.
21. Bruscoli M, Lovestone S. Is MCI really just early dementia? A systematic review of conversion studies. Int Psychogeriatr 2004; 16(2): 129-140.
22. Hampel H, Lista S, Khachaturian ZS. Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot. Alzheimers Dement 2012; 8(4): 312-336.
23. Cummings JL. Biomarkers in Alzheimer's disease drug development. Alzheimers Dement 2011; 7(3): e13-e44.
24. Cummings JL. Integrating ADNI results into Alzheimer's disease drug development programs. Neurobiol Aging 2010; 31(8): 1481-1492.
25. Ewers M, Sperling RA, Klunk WE, Weiner MW, Hampel H. Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci 2011; 34(8): 430-442.
26. Caroli A, Frisoni GB. The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort. Neurobiol Aging 2010; 31(8): 1263-1274.
27. Small GW, Siddarth P, Kepe V, et al. Prediction of cognitive decline by positron emission tomography of brain amyloid and tau. Arch Neurol 2012; 69(2): 215-222.
28. Small GW, Bookheimer SY, Thompson PM, et al. Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol 2008; 7(2): 161-172.
29. Small GW, Kepe V, Ercoli LM, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 2006; 355(25): 2652-2663.
30. Furst AJ, Kerchner GA. From Alois to Amyvid: seeing Alzheimer disease. Neurology 2012; 79(16): 1628-1629.
31. Doraiswamy PM, Sperling RA, Coleman RE, et al. Amyloid-beta assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology 2012; 79(16): 1636-1644.
32. Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 2009; 73(10): 754-760.
33. Koivunen J, Scheinin N, Virta JR, et al. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology 2011; 76(12): 1085-1090.
34. Edison P, Archer HA, Hinz R, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 2007; 68(7): 501-508.
35. Anchisi D, Borroni B, Franceschi M, et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol 2005; 62(11): 1728-1733.
36. Drzezga A, Grimmer T, Riemenschneider M, et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med 2005; 46(10): 1625-1632.
37. Mosconi L, Perani D, Sorbi S, et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 2004; 63(12): 2332-2340.
38. Fan Y, Batmanghelich N, Clark CM, Davatzikos C. Spatial patterns of brain atrophy in MCI patients, identified via high-dimensional pattern classification, predict subsequent cognitive decline. Neuroimage 2008; 39(4): 1731-1743.
39. Misra C, Fan Y, Davatzikos C. Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: results from ADNI. Neuroimage 2009; 44(4): 1415-1422.
40. Miller SL, Fenstermacher E, Bates J, et al. Hippocampal activation in adults with mild cognitive impairment predicts subsequent cognitive decline. J Neurol Neurosurg Psychiatry 2008; 79(6): 630-635.
41. Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease. Methods 2012; 56(4): 484-493.
42. Mattsson N, Andreasson U, Persson S, et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 2011; 7(4): 386-395 e6.
43. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6(3): 131-144.
44. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006; 59(3): 512-519.
45. Ost M, Nylen K, Csajbok L, et al. Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology 2006; 67(9): 1600-1604.
46. Hampel H, Burger K, Pruessner JC, et al. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol 2005; 62(5): 770-773.
47. Hampel H, Shen Y, Walsh DM, et al. Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol 2010; 223(2): 334-346.
48. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003; 2(10): 605-613.
49. Weiner MW, Veitch DP, Aisen PS, et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement 2012; 8(1 Suppl): S1-S68.
50. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367(9): 795-804.
51. Jack CR Jr, Vemuri P, Wiste HJ, et al. Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol 2011; 68(12): 1526-1535.
52. van Rossum IA, Vos S, Handels R, Visser PJ. Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. J Alzheimers Dis 2010; 20(3): 881-891.
53. Buchhave P, Minthon L, Zetterberg H, et al. Cerebrospinal fluid levels of beta-amyloid 1-42: but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012; 69(1): 98-106.
54. van Rossum IA, Visser PJ, Knol DL, et al. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. J Alzheimers Dis 2012; 29(2): 319-327.
55. Zhuo JM, Wang H, Pratico D. Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither? Trends Pharmacol Sci 2011; 32(9): 562-571.
56. Drago V, Babiloni C, Bartres-Faz D, et al. Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage. J Alzheimers Dis 2011; 26(Suppl 3): 159-199.
57. Mohs RC, Cohen L. Alzheimer's Disease Assessment Scale (ADAS). Psychopharmacol Bull 1988; 24(4): 627-628.
58. Zec RF, Landreth ES, Vicari SK, et al. Alzheimer Disease Assessment Scale: a subtest analysis. Alzheimer Dis Assoc Disord 1992; 6(3): 164-181.
59. Sano M, Raman R, Emond J, et al. Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease. Alzheimer Dis Assoc Disord 2011; 25(2): 122-127.
60. Hobart J, Cano S, Posner H, et al. Putting the Alzheimer's cognitive test to the test II: Rasch Measurement Theory. Alzheimers Dement 2013; 9(1 Suppl): S10-S20.
61. Molnar FJ, Man-Son-Hing M, Fergusson D. Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia. J Am Geriatr Soc 2009; 57(3): 536-546.
62. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43(11): 2412-2414.
63. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(Suppl 2): S22-S32.
64. Proust-Lima C, Amieva H, Dartigues JF, Jacqmin-Gadda H. Sensitivity of four psychometric tests to measure cognitive changes in brain aging-population-based studies. Am J Epidemiol 2007; 165(3): 344-350.
65. Amieva H, Meillon C, Helmer C, et al. Ginkgo biloba extract and long-term cognitive decline: a 20-year follow-up population-based study. PLoS One 2013; 8(1): e52755.
66. Amieva H, Le Goff M, Millet X, et al. Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. Ann Neurol 2008; 64(5): 492-498.
67. Small BJ, Backman L. Longitudinal trajectories of cognitive change in preclinical Alzheimer's disease: a growth mixture modeling analysis. Cortex 2007; 43(7): 826-834.
68. Luo Y, Smith JV, Paramasivam V, et al. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci USA 2002; 99(19): 12197-12202.
69. Samieri C, Feart C, Proust-Lima C, et al. omega-3 fatty acids and cognitive decline: modulation by ApoEepsilon4 allele and depression. Neurobiol Aging 2011; 32(12): 2317 e13-e22.
70. Blasko I, Hinterberger M, Kemmler G, et al. Conversion from mild cognitive impairment to dementia: influence of folic acid and vitamin B12 use in the VITA cohort. J Nutr Health Aging 2012; 16(8): 687-694.
71. Chapman RM, Mapstone M, McCrary JW, et al. Predicting conversion from mild cognitive impairment to Alzheimer's disease using neuropsychological tests and multivariate methods. J Clin Exp Neuropsychol 2011; 33(2): 187-199.
72. Smith T, Gildeh N, Holmes C. The Montreal Cognitive Assessment: validity and utility in a memory clinic setting. Can J Psychiatry 2007; 52(5): 329-332.
73. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12(3): 189-198.
74. Loewenstein DA, Barker WW, Harwood DG, et al. Utility of a modified Mini-Mental State Examination with extended delayed recall in screening for mild cognitive impairment and dementia among community dwelling elders. Int J Geriatr Psychiatry 2000; 15(5): 434-440.
75. Larner AJ. Screening utility of the Montreal Cognitive Assessment (MoCA): in place of--or as well as--the MMSE? Int Psychogeriatr 2012; 24(3): 391-396.
76. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53(4): 695-699.
77. Dong Y, Lee WY, Basri NA, et al. The Montreal Cognitive Assessment is superior to the Mini-Mental State Examination in detecting patients at higher risk of dementia. Int Psychogeriatr 2012; 24(11): 1749-1755.
78. Roalf DR, Moberg PJ, Xie SX, et al. Comparative accuracies of two common screening instruments for classification of Alzheimer's disease, mild cognitive impairment, and healthy aging. Alzheimers Dement: 2013; 9(5): 529-537.
79. Freitas S, Simoes MR, Alves L, Santana I. Montreal Cognitive Assessment: Validation Study for Mild Cognitive Impairment and Alzheimer Disease. Alzheimer Dis Assoc Disord 2013; 27(1): 37-43.
80. Larner AJ. Comparing diagnostic accuracy of cognitive screening instruments: a weighted comparison approach. Dement Geriatr Cogn Dis Extra 2013; 3(1): 60-65.
81. Kessels RP, Molleman PW, Oosterman JM. Assessment of working-memory deficits in patients with mild cognitive impairment and Alzheimer's dementia using Wechsler's Working Memory Index. Aging Clin Exp Res 2011; 23(5-6): 487-490.
82. Petersen RC. Mild cognitive impairment clinical trials. Nat Rev Drug Discov 2003; 2(8): 646-653.
83. Tabert MH, Manly JJ, Liu X, et al. Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment. Arch Gen Psychiatry 2006; 63(8): 916-924.
84. Summers MJ, Saunders NL. Neuropsychological measures predict decline to Alzheimer's dementia from mild cognitive impairment. Neuropsychology 2012; 26(4): 498-508.
85. Lee YM, Park JM, Lee BD, et al. Memory impairment, in mild cognitive impairment without significant cerebrovascular disease, predicts progression to Alzheimer's disease. Dement Geriatr Cogn Disord 2012; 33(4): 240-244.
86. Petersen RC. Mild cognitive impairment: where are we? Alzheimer Dis Assoc Disord 2005; 19(3): 166-169.
87. Brandt J, Aretouli E, Neijstrom E, et al. Selectivity of executive function deficits in mild cognitive impairment. Neuropsychology 2009; 23(5): 607-618.
88. Sacuiu S, Gustafson D, Johansson B, et al. The pattern of cognitive symptoms predicts time to dementia onset. Alzheimers Dement 2009; 5(3): 199-206.
89. Saunders NL, Summers MJ. Attention and working memory deficits in mild cognitive impairment. J Clin Exp Neuropsychol 2010; 32(4): 350-357.
90. Clark LR, Schiehser DM, Weissberger GH, et al. Specific measures of executive function predict cognitive decline in older adults. J Int Neuropsychol Soc 2012; 18(1): 118-127.
91. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology 2000; 55(11): 1621-1626.
92. Yamao A, Nagata T, Shinagawa S, et al. Differentiation between amnestic-mild cognitive impairment and early-stage Alzheimer's disease using the Frontal Assessment Battery test. Psychogeriatrics 2011; 11(4): 235-241.
93. Geda YE, Roberts RO, Knopman DS, et al. Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study. Arch Gen Psychiatry 2008; 65(10): 1193-1198.
94. Rosenberg PB, Mielke MM, Appleby BS, Oh ES, Geda YE, Lyketsos CG. The Association of Neuropsychiatric Symptoms in MCI With Incident Dementia and Alzheimer Disease. Am J Geriatr Psychiatry 2013; 21(7): 685-695.
95. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 2006; 63(5): 530-538.
96. Gao Y, Huang C, Zhao K, et al. Depression as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Int J Geriatr Psychiatry 2013; 28(5): 441-449.
97. Wetherell JL, Gatz M, Johansson B, Pedersen NL. History of depression and other psychiatric illness as risk factors for Alzheimer disease in a twin sample. Alzheimer Dis Assoc Disord 1999; 13(1): 47-52.
98. Kessing LV, Andersen PK. Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder? J Neurol Neurosurg Psychiatry 2004; 75(12): 1662-1666.
99. Dotson VM, Beydoun MA, Zonderman AB. Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. Neurology 2010; 75(1): 27-34.
100. Wuwongse S, Chang RC, Law AC. The putative neurodegenerative links between depression and Alzheimer's disease. Prog Neurobiol 2010; 91(4): 362-375.
101. Grunblatt E, Zehetmayer S, Bartl J, et al. Genetic risk factors and markers for Alzheimer's disease and/or depression in the VITA study. J Psychiatr Res 2009; 43(3): 298-308.
102. Borroni B, Archetti S, Costanzi C, et al. Role of BDNF Val66Met functional polymorphism in Alzheimer's disease-related depression. Neurobiol Aging 2009; 30(9): 1406-1412.
103. Caraci F, Bosco P, Signorelli M, et al. The CC genotype of transforming growth factor-beta1 increases the risk of late-onset Alzheimer's disease and is associated with AD-related depression. Eur Neuropsychopharmacol 2012; 22(4): 281-289.
104. Houde M, Bergman H, Whitehead V, Chertkow H. A predictive depression pattern in mild cognitive impairment. Int J Geriatr Psychiatry 2008; 23(10): 1028-1033.
105. Modrego PJ, Ferrandez J. Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type: a prospective cohort study. Arch Neurol 2004; 61(8): 1290-1293.
106. Lee GJ, Lu PH, Hua X, et al. Depressive symptoms in mild cognitive impairment predict greater atrophy in Alzheimer's disease-related regions. Biol Psychiatry 2012; 71(9): 814-821.
107. Starkstein SE, Jorge R, Mizrahi R, Robinson RG. The construct of minor and major depression in Alzheimer's disease. Am J Psychiatry 2005; 162(11): 2086-2093.
108. Shim YS, Yang DW. Depression as prognostic factor: 6 months follow-up in a geriatric institution. Arch Gerontol Geriatr 2006; 43(2): 277-283.
109. Lyketsos CG, Steele C, Baker L, et al. Major and minor depression in Alzheimer's disease: prevalence and impact. J Neuropsychiatry Clin Neurosci 1997; 9(4): 556-561.
110. Milwain EJ, Nagy Z. Depressive symptoms increase the likelihood of cognitive impairment in elderly people with subclinical Alzheimer pathology. Dement Geriatr Cogn Disord 2005; 19(1): 46-50.
111. Visser PJ, Scheltens P, Verhey FR. Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease? J Neurol Neurosurg Psychiatry 2005; 76(10): 1348-1354.
112. Lu PH, Edland SD, Teng E, et al. Donepezil delays progression to AD in MCI subjects with depressive symptoms. Neurology 2009; 72(24): 2115-2121.
113. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-571.
114. Vemuri P, Wiste HJ, Weigand SD, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 2009; 73(4): 287-293.
115. Brys M, Glodzik L, Mosconi L, et al. Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease. J Alzheimers Dis 2009; 16(2): 351-362.
116. Schmand B, Huizenga HM, van Gool WA. Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease. Psychol Med 2010; 40(1): 135-145.
117. Vemuri P, Wiste HJ, Weigand SD, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 2009; 73(4): 294-301.
118. Zhang D, Wang Y, Zhou L, Yuan H, Shen D. Multimodal classification of Alzheimer's disease and mild cognitive impairment. Neuroimage 2011; 55(3): 856-867.
119. Davatzikos C, Bhatt P, Shaw LM, Batmanghelich KN, Trojanowski JQ. Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification. Neurobiol Aging 2011; 32(12): 2322 e19-e27.
120. Heister D, Brewer JB, Magda S, Blennow K, McEvoy LK. Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology 2011; 77(17): 1619-1628.
121. Ewers M, Walsh C, Trojanowski JQ, et al. Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging 2012; 33(7): 1203-1214.
122. Cui Y, Liu B, Luo S, et al. Identification of conversion from mild cognitive impairment to Alzheimer's disease using multivariate predictors. PLoS One 2011; 6(7): e21896.
123. Zhang D, Shen D. Predicting future clinical changes of MCI patients using longitudinal and multimodal biomarkers. PLoS One 2012; 7(3): e33182.
124. Fjell AM, Walhovd KB, Fennema-Notestine C, et al. CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease. J Neurosci 2010; 30(6): 2088-2101.
125. Greenberg BD, Carrillo MC, Ryan JM, et al. Improving Alzheimer's disease phase II clinical trials. Alzheimers Dement 2013; 9(1): 39-49.
126. Vellas B, Aisen PS, Sampaio C, et al. Prevention trials in Alzheimer's disease: an EU-US task force report. Prog Neurobiol 2011; 95(4): 594-600.
127. Holland D, McEvoy LK, Desikan RS, Dale AM. Enrichment and stratification for predementia Alzheimer disease clinical trials. PLoS One 2012; 7(10): e47739.
128. Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 2010; 6(2): 108-119.
129. Bishop GM, Robinson SR, Smith MA, Perry G, Atwood CS. Call for Elan to publish Alzheimer's trial details. Nature 2002; 416(6882): 677.
130. Winblad B, Andreasen N, Minthon L, et al. Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 2012; 11(7): 597-604.
131. Delrieu J, Ousset PJ, Caillaud C, Vellas B. Clinical trials in Alzheimer's disease': immunotherapy approaches. J Neurochem 2012; 120(Suppl 1): 186-193.
132. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010; 9(11): 1118-1127.
133. A Study of Gantenerumab in Patients With Prodromal Alzheimer's Disease. http://www.clinicaltrials.gov/ct2/results?term=NCT01224106&Search=Search (accessed January 20: 2013).
134. Fagan T, Strobel G. The Solanezumab Benefit: Oh, So Small, But Probably Real http://www.alzforum.org/new/detail.asp?id=3288 (accessed January 20: 2013).
135. Strobel G, Zakaib GD. Solanezumab Heads for New Phase 3 Trial (accessed January 20: 2013).
136. Strobel G, Zakaib GD. Solanezumab Selected for Alzheimer's A4 Prevention Trial. http://www.alzforum.org/new/detail.asp?id=3379 (accessed July 1: 2013).
137. Sperling R, Donohue MPA. The A4 trial: Anti-amyloid treatment of asymptomatic Alzheimer's disease. Alzheimers Dement 2012; 8(4): 425-426.
138. G. DIAN Trial Picks Gantenerumab, Solanezumab, Maybe BACE Inhibitor http://www.alzforum.org/new/detail.asp?id=3289 (accessed January 20: 2013).
139. Wang SC, Oelze B, Schumacher A. Age-specific epigenetic drift in late-onset Alzheimer's disease. PLoS ONE, 2008; 3(7): e2698.
140. Caraci F, Leggio GM, Drago F, Salomone S. Epigenetic drugs for Alzheimer's disease: hopes and challenges. Br J Clin Pharmacol 2013; 75(4): 1154-1155.